Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
January 05, 2024 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to KIMMTRAK (tebentafusp-tebn)...
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 07:00 ET
|
Immunocore Holdings Limited
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 January, 2024) Immunocore Holdings plc...
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major...
Immunocore to present at upcoming investor conferences
June 01, 2023 16:30 ET
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 June 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany,...
Immunocore Announces $140 Million Private Placement Financing
July 18, 2022 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq:...
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
June 25, 2022 04:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor...
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
June 08, 2022 07:00 ET
|
Immunocore Holdings Limited
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable...
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved in the United States and European Union for the treatment of unresectable...
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
April 04, 2022 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved in the E.U. to...